A clinical case of the retroperitoneal fibrosis (Ormond's disease) in rheumatology practice

Abstract. Retroperitoneal fibrosis (RPF) is a rare disease characterized by the proliferation of inflammatory and fibrous tissue in the retroperitoneum. These masses are commonly localized around the infrarenal part of the abdominal aorta and iliac arteries, often covering the ureters or other organs of the abdominal cavity; idiopathic diseases accounting for 70% of cases. RPF may be associated with immunoglobulin G4 (IgG4), which accounts for two-thirds of idiopathic RPF cases. Secondary RPF may develop due to infections, malignant neoplasms, medication, retroperitoneal bleeding, or various other diseases. A clinical case of idiopathic RPF, probably associated with IgG4, was described in a patient who had undergone a symptomatic surgical treatment in an urological clinic and continued being treated by a rheumatologist, given pathogenetic therapy (methylprednisolone and mycophenolate mofetil) with a significant improvement. For rheumatologists, this pathology is of an undoubted clinical interest, since these changes are based on processes similar to those occurring in systemic diseases of the connective tissue, and the RPF is extremely rare, ranging from 0.1 to 1.3 cases per 100,000 patients per year. However, more often than not, such patients are referred to the doctors of ancillary specialties (urologists, nephrologists, surgeons, vascular surgeons). All of the abovementioned facts emphasize the importance of analyzing such a clinical case.

Keywords: retroperitoneal fibrosis; IgG4-associated disease; clinical case; diagnosis; treatment

Introduction

Retroperitoneal fibrosis (RPF) is a rare disease characterized by an inflammatory and fibrous tissue proliferation in the retroperitoneal area. These proliferations are localized around the infrarenal section of abdominal aorta and iliac arteries; they are often coating the ureters and other organs of abdominal cavity [1]. In 1984, the disease was first described by J. K. Ormond and named in his honour [2]. However, there are other names associated with this pathology: fibrous periurethritis, plastic periurethritis and fibrous retroperitonitis. The scientists distinguish between a primary (idiopathic) and secondary RPF; idiopathic conditions accounting for 70% cases. The RPF may be associated with G4 immunoglobulin (IgG4), which results in 2/3 of idiopathic RPF cases [3]. The secondary RPF may develop due to infections, malignant neoplasms, and a history of certain medications, retroperitoneal bleeding and other conditions. The RPF is a rather rare disease. According to various studies, the frequency of idiopathic (primary) conditions varies from 0.1 to 1.3 cases per 100,000 subjects annually [4]. The subjects aged 40–60 years, namely men, predominate in a ratio of 2:1 to 3:1. Some authors [5] refer to an increased RPF risk associated with tobacco smoke or asbestos.

The secondary RPF’s frequency is not yet clear. Over 70% cases are afflicted by the idiopathic RPF, which is an immune-mediated condition; it may develop both independently and accompany the IgG4-associated diseases. Among the pathogenetic factors, there are genetic associations with HLA-DRB1 antigen system under the environment factors such as asbestos and smoking. These agents affect the CD4+ T-cells of aorta and retroperitoneal area, promoting their proliferation and interleukin (IL) 6 secretion, and further on, activating the B-cells and fibroblasts [6]. The CD4+ T-cells are also secreting IL-4, IL-10, IL-13 and transforming growth factor beta (TGF-β), stimulating the B-cell proliferation and maturity into the plasmatic cells, and as a result they may provoke the predominance of IgG4-producing plasmatic cells [7].
This pathology may be of clinical interest for the rheumatologists, as these changes are based on the processes, similar to those attending the systemic connective tissue disorders. In this regard, we find it instructive to present our description of RPF case, undergoing symptomatic surgery at the urology clinic, and referred to the rheumatologist for the pathogenetic therapy.

**Clinical case**

In October 2020, the 62-year-old patient B. presented himself to a rheumatologist, complaining of lumbar pain generated by the physical activity, general weakness, headache, nausea and vomiting after food and water consumption, xerostomia, weight loss of up to 6 kg during the previous month due to a lack of appetite, body temperature surges up to 37.2-37.5 °C, headache and arterial blood pressure reaching 180/120 mm Hg.

Since August 2020, the patient considers himself sick. He gradually started to suffer from strangury, lower abdominal and lumbosacral pains, nausea and vomiting. He was examined by the family physician; due to a suspected renal pathology, he was referred to an urologist for consultation. The patient was admitted to the urology department from 4.09.2020 to 28.09.2020, and diagnosed with: a bilateral ureterohydronephrosis, chronic kidney disease (CKD) of stages III-IV, nephrogenic hypertension, massive neoplasm in the retroperitoneal area. The percutaneous nephrostomy was performed by direct puncture on the left side 17.09.2020, and on the right side 29.09.2020 (Fig. 1, patient’s photo).

Details of anamnesis vitae: tuberculosis, diabetes mellitus, patient denies viral hepatitis type A (Botkin’s disease), his father had a stroke. In 2000, the patient had appendectomy, peritonitis; in 2007, phimosis-related circumcision; in 2010, he had undergone repair of inguinal hernia on both sides.

The examination revealed an aggravated condition, forced posturing; the patient uses wheelchair due to the general weakness and dizziness. The peripheral lymph nodes are barely palpated. No peripheral edema present. The cutaneous covering is pure, coloring normal. There is a clear pulmonary sound over the whole lung perimeter; vesicular breathing at auscultation, no rales. The borders of relative cardiac dullness: the right border – the IV intercostal space on the right sternal edge; the upper border – the III intercostal space at the left parasternal line; the left border – the V intercostal space at the left medioclavicular line. At auscultation, the heart tones are muffled, the cardiac activity rhythmic, the 2 tone on the aorta is unclear, arterial blood pressure is 100/60 mm Hg. The heart rate is 88 beats per minute (bpm), satisfactory quality, rhythmic. The tongue is dry, furred with whitish-yellow deposit.

At palpation, the stomach is soft, not painful. The liver is palpated near the edge of costal arch, the spleen is not palpated. The costovertebral angle (CVA) tenderness is negative on both sides. There are nephrostomes inserted around both kidneys, in both urinals the liquid is light-yellow (300 ml in the right one, 1500 ml in the left one).

The stool is of normal color and consistency, no pathological substances added. The laboratory findings are presented in Tables 1 and 2.

Besides the above-mentioned tests, the patient had undergone the following lab examinations: 6.10.2020 C-reactive protein (CRP) - 60 mg/L, RF - 10 IU/mL, antinuclear antibody (ANA) test – 0.82 IU/mL (negative), carcinoembryonic antigen (CEA) test – 1.64 ng/mL (negative), iron – 16.4 μmol/L, total cholesterol – 4.73 mmol/L, triglycerides – 1.55 mmol/L, high-density lipoproteins (HDL) – 1.46 mmol/L, low-density lipoproteins (LDL) – 2.57 mmol/L, very-low-density lipoproteins (VLDL) – 0.70 mmol/L, atherogenic index – 2.20; coagulogram: International Normalized Ratio (INR) – 0.95, Quick value – 107.4 %, prothrombin time (PT) – 12.7; Fibrinogen (FF) – 5.6 g/L. Due to the epidemiological situation, the patient was examined for COVID infection (IgM SARS-CoV2) – 0.19 U (negative). 13.10.20 polymerase chain reaction (PCR) to SARS-CoV2 – 0.19 U (negative). The patient has an increased IgG level – 300 mg/dL (normal level up to 100 mg/dL).

The following instrumental studies were performed: chest X-ray: no infiltrating and inflammatory changes; thoracic X-ray: spondylosis deformans (Th₁₋₁), osteochondrosis (L₁₋₂), lumbar spine: diffuse spondylosis deformans, spondyloarthitis, osteochondrosis (L₁₋₃), signs of bilateral sacroiliitis. Magnetic resonance imaging (MRI) of sacroiliac joint (SIJ): no evidence of sacroiliac arthritis.

**Figure 1. Nephrostomies in retroperitoneal fibrosis patient**

Note. The written informed consent for participation and publication of data were given by the patient.
### Table 1. Complete blood count (CBC): patient B’s dynamics

| Dates            | Hemoglobin, g/L | Erythrocytes, x 10^12/L | Leukocytes, x 10^9/L | Platelets, x 10^9/L | Stab neutrophils, % | Segmented neutrophils, % | Eosinophils, % | Basophils, % | Monocytes, % | Lymphocytes, % | Monocytes, % | ESR rate, mm/hr |
|------------------|-----------------|--------------------------|----------------------|---------------------|---------------------|-------------------------|----------------|--------------|--------------|---------------|-------------|----------------|
| 06.10.2020       | 11.1            | 4.04                     | 10.3                 | 266                 | 71                   | 1                        | 0              | 2            | 32           | 28           | 2            | 43             |
| 09.10.2020       | 11.2            | 4.2                      | 10.9                 | 268                 | 72                   | 1                        | 0              | 3            | 30           | 29           | 2            | 40             |
| 12.10.2020       | 11.3            | 4.3                      | 11.0                 | 266                 | 71                   | 1                        | 0              | 3            | 32           | 28           | 2            | 40             |
| 15.10.2020       | 11.4            | 4.4                      | 11.2                 | 268                 | 68                   | 1                        | 0              | 3            | 28           | 30           | 2            | 40             |
| 18.10.2020       | 11.5            | 4.5                      | 11.3                 | 266                 | 71                   | 1                        | 0              | 3            | 32           | 28           | 2            | 40             |

Notes: ESR - erythrocyte sedimentation rate.

### Table 2. Blood biochemistry: patient B’s dynamics

| Dates            | Urea, mmol/L | Creatinine, mmol/L | Total bilirubin, μmol /L | Glucose, mmol/L | Potassium, mmol/L | Sodium, mmol/L | Total protein, g/L | Uric acid, μmol /L | Ferritin, ng/ L | ALT, IU/L | AST, IU/L | 25-OH Vitamin D, nmol/L |
|------------------|--------------|--------------------|--------------------------|-----------------|------------------|----------------|--------------------|-------------------|-----------------|-----------|-----------|----------------------|
| 06.10.2020       | 6.10         | 124                | 7164                     | 6.17            | 4.91             | 135            | 70.2               | 13.5              | 350             | 162       | 104       | 207                  |
| 09.10.2020       | 6.16         | 128                | 7164                     | 6.16            | 4.89             | 134.3          | 70.2               | 13.5              | 350             | 162       | 104       | 207                  |
| 12.10.2020       | 6.17         | 128                | 7164                     | 6.17            | 4.85             | 134.3          | 70.2               | 13.5              | 350             | 162       | 104       | 207                  |
| 15.10.2020       | 6.18         | 128                | 7164                     | 6.17            | 4.76             | 134.3          | 70.2               | 13.5              | 350             | 162       | 104       | 207                  |
| 18.10.2020       | 6.18         | 128                | 7164                     | 6.17            | 4.76             | 134.3          | 70.2               | 13.5              | 350             | 162       | 104       | 207                  |

Notes: ALT- Alanine transaminase, AST- aspartate transaminase.

### Clinical Case

`...`

Pulmonary hypertension. The ultrasound examination of the abdominal organs and kidneys: no signs of diffuse pathology of liver parenchyma, signs of chronic glomerulonephritis, signs of chronic polyneuropathy. Insignificant bilateral pyelonephritis. Signs of diffuse pathology of kidney parenchyma with bilateral pyelonephritis signs. The ultrasound examination of the abdominal organs and kidneys: no signs of diffuse pathology of liver parenchyma, signs of chronic glomerulonephritis, signs of chronic polyneuropathy. Insignificant bilateral pyelonephritis. Signs of diffuse pathology of kidney parenchyma with bilateral pyelonephritis signs. The ultrasound examination of the abdominal organs and kidneys: no signs of diffuse pathology of liver parenchyma, signs of chronic glomerulonephritis, signs of chronic polyneuropathy. Insignificant bilateral pyelonephritis. Signs of diffuse pathology of kidney parenchyma with bilateral pyelonephritis signs. The ultrasound examination of the abdominal organs and kidneys: no signs of diffuse pathology of liver parenchyma, signs of chronic glomerulonephritis, signs of chronic polyneuropathy. Insignificant bilateral pyelonephritis. Signs of diffuse pathology of kidney parenchyma with bilateral pyelonephritis signs.

The patient was consulted by a surgeon and oncologist at the Kharkiv Oncology Center: biopsy is impossible due to a threat to the patient’s life.

Taking into account the MSCT and ultrasound findings, revealing the renal function disorder, ureteric obstruction, periaortitis, and ruling out the secondary causes of tumor-like neoplasm, as well as the latter’s characteristic location, the patient was diagnosed with the following: Primary diagnosis: Idiopathic retroperitoneal fibrosis.
(Ormond’s disease) - periureteric fibrosis with ureteric obstruction. Bilateral ureterohydronephrosis. Percutaneous nephrostomy and direct puncture on the left 17.09.2020 and on the right 29.09.2020. Complications of the primary diagnosis: CKD of stage IV (EPI glomerular filtration rate (GFR) – 31 mL/min/1.73 m²), vascular lesions: periaortitis with abdominal aorta involvement, common iliac arteries, upper and lower mesenteric, renal arteries, engaging postcava at the level of infrahepatic compartment (CT data of 25.09.20). Secondary nephrogenic arterial hypertension of stage 2, degree 2, high risk, heart failure (HF) of stage 1. Lymphadenopathy: retroperitoneal lymphadenopathy. Attending diagnosis: Vitamin D deficiency. Ulcer disease, active phase, active duodenal bulb ulcer. Chronic atrophic hyperplastic erosive gastroduodenitis with acid-producing gastric function. Diaphragm ulcer. Chronic noncalculous cholecystitis, beyond complications. Chronic pancreatitis, beyond complications. A possible diagnosis relevant for this patient – probable IgG4–associated condition, according
to H. Umehara et al.’s comprehensive criteria [8], as there is a retroperitoneal fibrosis and IgG4’s increase up to 135 mg/dL. However, the modern ACR/EULAR diagnostic criteria imply 20 points and over, while the present case has only 14 points [9]. This patient’s biopsy was not performed due to some technical difficulties and threats to his life, reflected in the oncologist’s and surgeon’s conclusions. We have performed a thorough oncological search, and malignant neoplasm was ruled out.

The patient was treated at the rheumatology department (Dexamethasone IV for 5 days in a row, 48 mg Methylprednisolone tablet a day, glucose, insulin, 1 mL Metoclopramide intramuscularly for 7 days, 5 mg Concor a day, 20 mg Omeprazole twice a day), as well as receiving medication for ulcer disease (antibacterial therapy, Bismuth medications) with a minor positive effect of reduced shortness of breath (SOB), nausea, reduced urea and creatinine indices, duodenal ulcer scarring; however, the pathogenetic therapy implies immunosuppressive treatment. According to the reference data, glucocorticoids calculated as 1 mg/kg by prednison are considered the key method of idiopathic retroperitoneal fibrosis (RPF) [10]. On discharge, the patient was prescribed a daily 48 mg Methylprednisolone dose and 4000 IU Vitamin D dose, and as a result a certain positive dynamics was achieved, both in terms of general health and urea and creatinine level reduction. However, taking into account the nitrogen metabolism and general lab activity, no positive dynamics registered by MSCT (the size of infiltrative paraaortal neoplasm remains intact, aorta is thickened diffusely) in November 2020, the patient was prescribed an additional daily 2 g dose of Mycophenolate mofetil (MMF). The MMF prescription was based on the recent randomized control trial, where 69 patients with IgG4-associated condition and RPF were receiving either a glucocorticoid (GC) monotherapy (initial dose of 0.6-0.8 mg/kg) or a combined GC and MMF therapy in a low dose (1.0-1.5 g/day) [11]. After 1 month, the effectiveness of two regimens of immunosuppressive therapy was comparable; however, after 1 year, the patients receiving the combined therapy had a significant increase of remission frequency (76.5 % vs. 51.4 %) and reduction of cumulative relapse frequency (20.6 % vs. 40.0 %). There is a high frequency of RPF relapses, remote adverse effects and a lack of disease control associated with GC monotherapy; one also emphasizes the necessity of combined GC and immunosuppressive medication use [12].

At the follow-up visit of 10.12.2020, there was a registered general health improvement, the shortness of breath, nausea disappeared, the urea level reduced to 10.0 mmol/L and creatinine to 151 μmol /L, hemoglobin level normalized, the inflammatory activity index (ESR) of 11 mm/hour, CRP of 6 mg/L. The patient continues taking MMF in a dose of 2 g per day, the Methylprednisolone dose should be reduced by 2 mg per week under the activity control, while the Vitamin D use should be continued. The patient is referred for a repeat urologist’s consultation to determine the further treatment tactics. On 16.12.2020, the antegrade pyelography was performed: there is a positive dynamic – the right ureter is patent, though the left kidney blockage is preserved at the level of upper third of left ureter (Fig. 4). The principal condition’s treatment is to be continued, with a control session after 3 months.

Discussion

According to the reference data [10], one should monitor the patient’s response to medication during the first month after the initiation, in order to assess the improvement of clinical symptoms, cessation of pain and release of obstruction. In the future, the clinical assessment of symptoms and lab results, namely the ESR, CRP and creatinine, should be performed every 2-3 months. The MSCT is performed a month after the therapy initiation,

Figure 3. Ultrasound examination of abdominal organs

Notes: Echo-irregular tissue neoplasm of 17 to 23 mm, located circularly along the anterior wall of abdominal aortic segment (A), with the Doppler color flow mapping (B).
then about every 4-6 months, to watch over the size of fibrous masses. Further on, the retroperitoneal fibrosis patient should be examined every 6-12 months, the MSCT performed every 1-2 years. Some researchers describe the cases of relapse occurring 10 years after the therapy termination [13].

While analyzing this clinical case, one should emphasize the following points.

It is the first time we’re facing such a rare pathology as retroperitoneal fibrosis. Its frequency varies from 0.1 to 1.3 cases per 100,000 subjects a year. That’s why our clinical observation has a doubtless value due to an experience we’ve gained while diagnosing and curing the patient (who is still on our watch).

Urological surgery on its own has a purely symptomatic function; it does not modify the course or continuing progression of fibrous changes.

No doubt, the pathohistological examination would assist in differentiation of isolated RPF from the IgG4-associated one. However, in the present circumstances biopsy is not always possible due to the technical issues. Besides, the patients with a typical fibrous mass localization and no clinical or lab manifestations of malignant process do not require an open biopsy or surgery unless the mass is not regressing with obstruction-releasing medication. There is no difference in treatment for the isolated or the IgG4-associated form. This is why we initiated the pathogenetic treatment without any pathohistological examination.

Prescribing cytostatic pathogenetic therapy (Methyprednisolone and MMF), we have managed to reduce the clinical manifestations considerably and to improve the patient’s life quality.

To sum up, RPF is an extremely rare and difficult-to-cure pathology; it is of great interest for both the rheumatologists and ancillary specialists (urologists, nephrologists, surgeons, vascular surgeons). This fact is attributed to the rarity, i.e. the patients addressing the surgeons, nephrologists, urologists for help are sent in for surgery. On the other hand, there are no clear-cut methods of diagnostic verification, the diagnostic criteria being complex and decision-making on the systemic glucocorticoid and cytostatic therapy (in case of massive fibrous proliferations compressing vessels and internal organs of various localizations) takes a long time, delaying the adequate treatment. The grave lesions of internal organs, as well as an inclination for relapse, compromise the life quality and require a regular monitoring. It is vital to discuss similar rare cases in order to raise awareness among the physicians and to provide a joint multidisciplinary treatment of such patients by rheumatologists, urologists, nephrologists, cardiologists and other specialists.

Conclusions

The Ormond’s disease (retroperitoneal fibrosis) should be thoroughly studied, and the standards of treatment should be developed in order to secure the well-being of patients with this pathology.

The immunosuppressive therapy should be prescribed at the earliest possible time, in order to prevent the irreversible fibrosis.

With advanced stages, one should proceed to a complex treatment, involving both medication and surgery.

Conflicts of interests. Authors declare the absence of any conflicts of interests and their own financial interest that might be construed to influence the results or interpretation of their manuscript.

Funding: no.

Authors’ individual contributions: Yehudina Ye.D., Trypilka S.A. - concept and design of the study; Trypilka S.A. - collection of data; Yehudina Ye.D., Trypilka S.A. - analysis and interpretation of data; Yehudina Ye.D. – writing the article; Trypilka S.A. - editing the article.

References

1. Vaglio A, Marituti F. Idiopathic Retroperitoneal Fibrosis. J Am Soc Nephrol. 2016 Jul;27(7):1880-9. doi: 10.1681/ASN.2015101110. CrossRef PubMed
2. Ormond JK. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J Urol. 1948 Jun;59(6):1072-9. doi: 10.1016/s0022-5347(17)69482-5. CrossRef PubMed
3. Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015 Apr 11;385(9976):1460-71. doi: 10.1016/s0140-6736(14)60720-0. CrossRef PubMed
4. van Bommel EFH, Jansen I, Hendriksz TR, Aarnoudse ALHJ. Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore). 2009 Jul;88(4):193-201. doi: 10.1097/MD.0b013e318181a6c20. CrossRef PubMed
5. Goldoni M, Bonini S, Urban ML, et al. Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: a case-control study. Ann Intern Med. 2014 Aug 5;161(3):181-8. doi: 10.7326/M13-2648. CrossRef PubMed
6. Della-Torre E, Rigamonti E, Perugini C, et al. B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease. J Allergy Clin Immunol. 2020 Mar;145(3):968-981.e14. doi: 10.1016/j.jaci.2019.07.004. CrossRef PubMed

Figure 4. Antegrade pyelography. The right ureter is patent, left kidney blockage at the level of upper third of left ureter
Клінічний випадок / Clinical Case

7. Matteo H, Mahajan VS, Machara T, et al. Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol. 2016 Sep;138(3):825-838. doi: 10.1016/j.jaci.2015.12.1330. CrossRef PubMed
8. Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD). 2011. Mod Rheumatol. 2012;22(1):21-30. doi: 10.1007/s10165-011-0571-z. CrossRef PubMed
9. Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. Arthritis Rheumatol 2020;72(1):7-19. doi: 10.1002/art.41120. CrossRef PubMed
10. Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015 Jul;67(7):1688-99. doi: 10.1002/art.39132. CrossRef PubMed

Резюме. Забрюшинний (ретроперitoneальний) фіброз (РПФ) — рідкісне захворювання, що має приналежність до системних захворювань сполучної тканини. Ідіопатичні інтерес, оскільки в основі цих змін лежать процеси, аналогічні таким при системних захворюваннях сполучної тканини, і незвичайно в ревматолога патогенетичною терапією (метилпреднизолон і мофетилу мікофенолат) зі значним поліпшенням.

11. Yunyun F, Yu P, Panpan Z, et al. Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology (Oxford). 2019 Jan 1;58(1):52-60. doi: 10.1093/rheumatology/key227. CrossRef PubMed
12. Wallace ZS, Kawano M, Sacki T, Nakashima H. IgG4-related kidney disease and retroperitoneal fibrosis: an update. Mod Rheumatol. 2019 Mar;29(2):231-239. doi: 10.1080/14397959.2018.1554321. CrossRef PubMed
13. Surcel C, Mirvald C, Puvlescu C, et al. Management of idiopathic retroperitoneal fibrosis from the urologist’s perspective Ther Adv Urol. 2015 Apr;7(2):85-99. doi: 10.1177/1756287214565637. CrossRef PubMed

Received 25.01.2021
Revised 15.02.2021
Accepted 02.03.2021

Трипілка С.А.1, Єгудіна Є.Д.2
1 Комуннальне некомерційне підприємство Харківської обласної ради «Обласна клінічна лікарня», м. Харків, Україна
2 Клініка сучасної ревматології, г. Київ, Україна

Ключові слова: ретроперitoneальний фіброз; IgG4-асоційована захворювання; урологія; нефрологія

Клінічний випадок розвитку ретроперitoneального фіброзу (хвороби Ормонда) у практиці ревматолога

Резюме. Забрюшинний (ретроперitoneальний) фіброз (РПФ) — рідкісне захворювання, що характеризується розростанням запальної та фіброзної тканини в заочеревинному просторі. Зазвичай ці розростання локалізуються навколо інфрахіазимальної часини черевної аорти та клубових артерій, часто покриваючи сечоводи або інші органи черевної порожнини. Ідіопатичні захворювання становлять 70 % випадків, часто покриваючи сечоводи або інші органи черевної порожнини. Ідіопатичні захворювання становлять 70 % випадків, часто покриваючи сечоводи або інші органи черевної порожнини. Ідіопатичні захворювання становлять 70 % випадків, часто покриваючи сечоводи або інші органи черевної порожнини. Ідіопатичні захворювання становлять 70 % випадків, часто покриваючи сечоводи або інші органи черевної порожнини.
розвиватися вслідство інфекцій, злояківствених новооформлень, приєма лекарствених препаратів, забрюшинного кровотечення або друхіх заболевань. Описан клиничний слід ідіопатичного РПФ, вероятно, асоційованого з IgG4, у пацієнта, прошедшого симптоматичне оперативне лікування в урологічній клініці і продовжившого лікування у ревматолога патогенетичною терапією (метилпреднизолон і мофетила мікофенолат) з значним увілам. Для ревматологів дана патологія представляє безусловний клиничний інтерес, по скольку, з однієї сторони, в основі даних змін лежать процеси, аналогічні таковим при системних заболеваннях соединительной ткани, а з іншої — це рідка патологія, відомість РПФ складає від 0,1 до 1,3 слів на 100 000 осіб в рік. Однак часто такі пацієнти само переходять на прийом до врачів смежних спеціальностей (урологів, нефрологів, хірургів, сосудистих хірургів), що підкреслює важливість розбору такого клиничного сліду.

Ключові слова: ретроперитонеальний фіброз; IgG4-ассоційоване заболявання; клиничний слід; діагностика; лікування